Performance of serum soluble interleukin-2 receptor as a diagnostic marker for lymphoma in patients with fever

There have been few reports on the diagnostic performance of soluble interleukin-2 receptor (sIL-2R) for lymphoma. A cross-sectional study was conducted at a university hospital; all patients who were admitted to the Division of General Internal Medicine and underwent serum sIL-2R testing were included. Patients were divided into two groups based on the presence of fever (≥ 38.0 °C). Among 602 patients, 421 had fever and 76 were diagnosed with lymphoma (48 of the 76 were in the febrile group). In all patients, the area under the receiver operating characteristic curve (AUROC) of sIL-2R for the diagnosis of lymphoma was 0.81 [95% confidence interval (CI), 0.75–0.87]. The AUROC was significantly higher in the febrile group (0.88; 95% CI, 0.81–0.94) than in the afebrile group (0.75; 95% CI, 0.65–0.85). In the febrile group, the sensitivity and specificity were 81.2% and 82.3%, respectively, with an optimal cutoff value of 3,250 U/mL. In the afebrile group, they were 89.3% and 54.9%, respectively, with a cutoff value of 868 U/mL. Serum sIL-2R showed high performance as an adjunctive diagnostic marker for lymphoma, particularly among febrile patients. Different cutoff values should be used for patients with and without fever to maximize diagnostic performance.


Statistical analyses
Continuous variables are presented as medians and interquartile ranges (IQRs) and compared using the Wilcoxon signed-rank test.Categorical variables were compared using McNemar's chi-square test.The sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of sIL-2R, WBC, PLT, and LDH levels for the diagnosis of lymphoma were determined.The area under the ROC curve (AUROC) was measured to estimate diagnostic performance, and the optimal cutoff values were determined using Youden's index.The ROC curves of the febrile group were compared with those of the afebrile group using the DeLong test.All P-values were two-tailed; P-values < 0.05 were considered statistically significant.All statistical analyses were performed using R (version 4.1.1,R Foundation for Statistical Computing, Vienna, Austria).

Results
A total of 625 patients were included in this study.We excluded 23 patients on chronic hemodialysis from further analysis because serum sIL-2R levels during hemodialysis can be elevated regardless of the presence of lymphoma or other disease 7,8 .Patient characteristics are shown in Table 1.Of the 602 patients, 337 (56%) were men, and 421 (70%) had fever.The degree of fever was not identified in one febrile patient, but a record of "high grade fever" before hospitalization was mentioned.
Of the 602 patients, 76 (13%) were diagnosed with lymphoma (48 in the febrile group and 28 in the afebrile group).The median serum sIL-2R level was significantly higher in patients with lymphoma than in those without lymphoma (5,170 U/mL vs. 1,145 U/mL, P < 0.001).In the febrile group, the median sIL-2R levels were significantly higher in patients with lymphoma than in those without lymphoma (8,460 U/mL [IQR, 3,545-16,650 U/mL] and 1,240 U/mL [IQR, 721-2,450 U/mL], respectively).In the afebrile group, similar significant trends with relatively low sIL-2R levels were observed; the median sIL-2R levels were 1,895 U/mL (IQR, 981-5,560 U/ mL) in afebrile patients with lymphoma and 797 U/mL (IQR, 496-1,520 U/mL) in those without lymphoma.In the febrile group, WBC and PLT counts were significantly lower, and monocyte percentage, monocyte-tolymphocyte ratio, and LDH levels were significantly higher in patients with lymphoma than in those without lymphoma, although there was no significant difference between patients with and without lymphoma in the afebrile group (Table 1).
Table 2 shows the final diagnoses of patients who participated in the analysis.A total of 76 patients (12.6%) were diagnosed with lymphoma; 31 had diffuse large B-cell lymphoma (17 belonged to the afebrile group), eight had intravascular lymphoma (all belonged to the febrile group), seven had follicular lymphoma (six belonged to the afebrile group), four had extranodal NK/T-cell lymphoma (all belonged to the febrile group), four had Hodgkin's lymphoma (three belonged to the febrile group), three had angioimmunoblastic T-cell lymphoma, three had adult T-cell leukemia/lymphoma, and 16 had lymphoma of other or uncertain subtype.Seven patients presented with lymphoma-associated hemophagocytic lymphohistiocytosis.In total, 22 patients, all of whom belonged to the febrile group, were diagnosed with hemophagocytic lymphohistiocytosis (seven lymphoma-associated, four infection-associated, six autoimmune disease-associated, and five other or unknown etiology).Hematologic disorders other than lymphoma and hemophagocytic lymphohistiocytosis included 14 lymphoproliferative disorders (eight Epstein-Barr virus-or methotrexate-associated lymphoproliferative disorders and six idiopathic multicentric Castleman disease [iMCD] or iMCD-TAFRO syndrome; these lymphoproliferative disorders were not histologically proven as lymphoma) and seven hypereosinophilic syndromes.
The distribution of serum sIL-2R levels according to the disease category is shown in Table 4.Among patients diagnosed with diseases other than lymphoma, 15% (78/526) had serum sIL-2R levels above 3250 U/mL.In addition to lymphoma, a certain number of patients with hematologic disorders, such as hemophagocytic lymphohistiocytosis, lymphoproliferative disorder, and hypereosinophilic syndrome, tuberculosis, rickettsiosis, and adverse drug reactions showed markedly elevated sIL-2R levels above 5000 U/mL.

Discussion
This study showed that the diagnostic performance of serum sIL-2R for lymphoma was significantly improved by stratifying the presence of fever, and that different cutoff values should be used for patients with or without fever.The majority of lymphoma subtypes among febrile patients in this study were aggressive lymphomas, including diffuse large B-cell lymphoma, intravascular lymphoma, extranodal NK/T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and adult T-cell leukemia/lymphoma.Although aggressive lymphoma requires prompt diagnosis and treatment, it is sometimes not associated with lymphadenopathy or mass formation and performing biopsies for the confirmation of diagnosis is difficult.Zhang    www.nature.com/scientificreports/showed poorer performance status, poorer prognosis, and lower complete remission rate than patients with lymphoma without a history of fever of unknown origin 9 .Our results indicate that serum sIL-2R levels may provide important information for estimating the probability of lymphoma and for considering the adoption of further imaging studies, such as positron emission tomography-computed tomography or aggressive biopsy, particularly for febrile patients.
The AUROC of sIL-2R in afebrile patients (0.75) was lower than that in febrile patients (0.88).Murakami et al. evaluated the diagnostic performance of 248 adult patients who were suspected to have lymphoma and had serum sIL-2R tested at a Japanese university hospital.They reported that the AUROC, sensitivity, and specificity were 0.695, 35%, and 93%, respectively, when the sIL-2R cutoff was set at 1,950 U/mL 6 .Their overall results were similar to our results for the afebrile group, mainly because their study included a small fraction of febrile patients (41 of 248 patients, 16%).Studies examining the utility of sIL-2R in the diagnosis of lymphoma are limited; Higashi et al. analyzed the values of sIL-2R in patients who underwent random skin biopsy for the diagnosis of intravascular lymphoma and suggested that high levels of sIL-2R may be one of the diagnostic indicators of the disease 10 .
Although serum sIL-2R levels showed good discriminating power in febrile patients in our study, the role of sIL-2R testing in the diagnosis of lymphoma is complementary, and false positives and negatives should be considered.The levels of sIL-2R are elevated in hematologic diseases other than lymphoma.For example, hemophagocytic lymphohistiocytosis is associated with sIL-2R elevation and is considered a marker for disease activity and prognosis [11][12][13] .Elevation of sIL-2R levels in patients with hypereosinophilic syndrome has also been reported in previous studies 14,15 .These observations are consistent with our study in which 6 of the 15 patients with non-lymphoma-associated hemophagocytic lymphohistiocytosis and three of the seven patients with hypereosinophilic syndrome had sIL-2R levels above 3250 U/mL.
In addition to hematologic disorders, sIL-2R elevation has been observed in various autoimmune, inflammatory, and infectious diseases, including systemic lupus erythematosus, adult-onset Still's disease, sarcoidosis, tuberculosis, and rickettsial infections [16][17][18][19] .In the present study, the sIL-2R levels in 43% (6/14) of patients with tuberculosis and 75% (3/4) of patients with rickettsial infections were > 3250 U/mL; therefore, we should consider these diseases in addition to lymphomas when sIL-2R levels are elevated in patients with fever of unknown origin.Eighteen patients in this study were diagnosed with having experienced drug reactions; among them, 12 exhibited sIL-2R levels of 2000 U/mL or higher.Several studies have reported elevated sIL-2R levels among patients with drug-induced adverse events 20,21 .Kluge et al. measured cytokine levels in patients who started clozapine and reported that the levels of interleukin-6 and sIL-2R were increased in patients who developed drug-induced fever, suggesting that drug reactions may activate inflammatory cytokines, resulting in the elevation of sIL-2R levels 20 .
In a real-world setting, some patients do not obtain a final diagnosis for a variety of reasons, such as the patients or their households do not wish to undergo invasive examination, or the patient's critically-ill condition does not allow for evaluation.In this study, there were four patients who were strongly suspected to have www.nature.com/scientificreports/lymphoma but this was not confirmed histologically; we categorized these patients into the non-lymphoma group (final diagnosis was not identified).However, the diagnostic performance remained approximately the same when they were categorized into the lymphoma group: the AUROC (95% CI) was 0.81 (0.75-0.87) in all patients, 0.88 (0.81-0.94) in the febrile group, and 0.75 (0.65-0.85) in the afebrile group.We excluded patients on chronic hemodialysis from our study because sIL-2R levels may be elevated by factors other than active disease.The mechanism is thought to involve a combination of factors, including decreased renal clearance and increased production of sIL-2R due to exposure to cytokine elicitors in the dialysate solution 7,8 .A preliminary, unpublished subgroup analysis from our study showed that the median serum sIL-2R level of patients without lymphoma on chronic hemodialysis (n = 23) was significantly higher than that of nonlymphoma patients not on hemodialysis: 3880 U/mL (IQR, 2122-7932 U/mL) vs. 1230 U/mL (IQR, 718-2380 U/mL) in the febrile group and 1720 U/mL (IQR, 1255-1720 U/mL) vs. 797 U/mL (IQR, 496-1520 U/mL) in the afebrile group.In our study, none of the patients with lymphoma underwent chronic hemodialysis.Further independent studies are warranted for patients on hemodialysis to assess the diagnostic performance of serum sIL-2R in lymphoma.
The present study has several limitations.First, this was a single-center study that enrolled patients who were hospitalized at the Division of General Internal Medicine.Therefore, there may have been a bias in the patient population.The participants of this study were predominantly older patients, and it is uncertain whether our results can be generalized to younger patients.Although patients who did not require hospitalization for diagnosis and those who were referred to our hospital with a confirmed diagnosis of lymphoma were not included, the results of our study may provide important insight into estimating the likelihood of lymphoma for a population that is hospitalized for examination of fever.Second, we defined fever as an axillary temperature of ≥ 38.0 °C.The definition of fever can vary across studies, and the degree of fever can be affected by medications, such as antipyretics.Third, this study included patients for whom a final diagnosis could not be obtained even after close examination or for whom further examination was not attempted based on their condition or willingness.Therefore, some cases of lymphoma may be misclassified as non-lymphoma.Fourth, patients diagnosed with lymphoma might have a certain simultaneous complication (e.g., a secondary bacterial infection) that can affect sIL-2R levels, which may have affected the performance of sIL-2R for the diagnosis of lymphoma.Finally, this retrospective study used medical records, which limited the reliability of the information.
In conclusion, this study showed that serum sIL-2R levels are a useful adjunctive diagnostic tool for lymphoma, particularly in febrile patients.To maximize the sensitivity and specificity for lymphoma, cutoff values of serum sIL-2R should be categorized based on the presence or absence of fever.The optimal cutoff levels for patients on hemodialysis remains a subject for future research.

Figure 1 .
Figure 1.Receiver operating characteristic curve analysis of serum sIL-2R levels for predicting lymphoma in all patients (A), febrile patients (B), and afebrile patients (C).AUROC area under the receiver operating characteristic curve, sIL-2R soluble interleukin-2 receptor, Se sensitivity, Sp specificity.

Table 1 .
Patient characteristics and biomarkers used.Data are presented as median (interquartile range) unless otherwise indicated.sIL-2R soluble interleukin-2 receptor, M/L ratio monocyte-to-lymphocyte ratio, LDH lactate dehydrogenase, ESR erythrocyte sedimentation rate.

Table 2 .
Final diagnosis of the study participants.